A cell-based chemical-genetic screen for amino acid stress response inhibitors reveals torins reverse stress kinase GCN2 signaling.


Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
12 2022
Historique:
received: 19 07 2022
revised: 07 10 2022
accepted: 10 10 2022
pubmed: 24 10 2022
medline: 6 1 2023
entrez: 23 10 2022
Statut: ppublish

Résumé

mTORC1 and GCN2 are serine/threonine kinases that control how cells adapt to amino acid availability. mTORC1 responds to amino acids to promote translation and cell growth while GCN2 senses limiting amino acids to hinder translation via eIF2α phosphorylation. GCN2 is an appealing target for cancer therapies because malignant cells can harness the GCN2 pathway to temper the rate of translation during rapid amino acid consumption. To isolate new GCN2 inhibitors, we created cell-based, amino acid limitation reporters via genetic manipulation of Ddit3 (encoding the transcription factor CHOP). CHOP is strongly induced by limiting amino acids and in this context, GCN2-dependent. Using leucine starvation as a model for essential amino acid sensing, we unexpectedly discovered ATP-competitive PI3 kinase-related kinase inhibitors, including ATR and mTOR inhibitors like torins, completely reversed GCN2 activation in a time-dependent way. Mechanistically, via inhibiting mTORC1-dependent translation, torins increased intracellular leucine, which was sufficient to reverse GCN2 activation and the downstream integrated stress response including stress-induced transcriptional factor ATF4 expression. Strikingly, we found that general translation inhibitors mirrored the effects of torins. Therefore, we propose that mTOR kinase inhibitors concurrently inhibit different branches of amino acid sensing by a dual mechanism involving direct inhibition of mTOR and indirect suppression of GCN2 that are connected by effects on the translation machinery. Collectively, our results highlight distinct ways of regulating GCN2 activity.

Identifiants

pubmed: 36273589
pii: S0021-9258(22)01072-9
doi: 10.1016/j.jbc.2022.102629
pmc: PMC9668732
pii:
doi:

Substances chimiques

Amino Acids 0
Eukaryotic Initiation Factor-2 0
Leucine GMW67QNF9C
Mechanistic Target of Rapamycin Complex 1 EC 2.7.11.1
TOR Serine-Threonine Kinases EC 2.7.11.1
EIF2AK4 protein, human EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

102629

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest P. J. M. is on the scientific advisory boards of Palleon Pharmaceuticals and ImCheck Pharma, neither of which have activities or interests related to this article. The authors declare that they have no conflicts of interest with the contents of this article.

Auteurs

Johanna B Brüggenthies (JB)

Max Planck Institute for Biochemistry, Martinsried, Germany.

Alessandra Fiore (A)

Max Planck Institute for Biochemistry, Martinsried, Germany.

Marion Russier (M)

Max Planck Institute for Biochemistry, Martinsried, Germany.

Christina Bitsina (C)

Max Planck Institute for Biochemistry, Martinsried, Germany.

Julian Brötzmann (J)

Max Planck Institute for Biochemistry, Martinsried, Germany.

Susanne Kordes (S)

Lead Discovery Center GmbH, Dortmund, Germany.

Sascha Menninger (S)

Lead Discovery Center GmbH, Dortmund, Germany.

Alexander Wolf (A)

Lead Discovery Center GmbH, Dortmund, Germany.

Elena Conti (E)

Max Planck Institute for Biochemistry, Martinsried, Germany.

Jan E Eickhoff (JE)

Lead Discovery Center GmbH, Dortmund, Germany.

Peter J Murray (PJ)

Max Planck Institute for Biochemistry, Martinsried, Germany. Electronic address: murray@biochem.mpg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH